Challenges in diagnosing latent tuberculosis infection in patients treated with tumor necrosis factor antagonists

Journal of Rheumatology

Volumn 38, Issue 7, 2011, Pages 1234-1243

  Keystone, Edward C ^a   Papp, Kim A ^b   Wobeser, Wendy ^c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b PROBITY MEDICAL RESEARCH   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Anergy; Delayed hypersensitivity; Interferon ; Latent tuberculosis infection; Tuberculin test; Tumor necrosis factor

Indexed keywords

ISONIAZID; METHOTREXATE; PREDNISONE; RIFAMPICIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR;

BCG VACCINATION; DIAGNOSTIC ACCURACY; DRUG MEGADOSE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HIGH RISK POPULATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGICAL TOLERANCE; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SENSITIVITY AND SPECIFICITY; TUBERCULIN TEST; TUBERCULOSIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FALSE NEGATIVE REACTIONS; FALSE POSITIVE REACTIONS; HUMANS; INTERFERON-GAMMA; LATENT TUBERCULOSIS; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79960066890     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100623     Document Type: Review

References (71)

1. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 2006;43:717-22. (Pubitemid 44330734)
2. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis 2004;39:1254-5. (Pubitemid 40169331)
3. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884-94.
4. Wallis RS. Tumour necrosis factor antagonists: structure, function, and tuberculosis risks. Lancet Infect Dis 2008;8:601-11.
5. Scallon B, Cai A, Solowski N, Rosenberg A, Song XY, Shealy D, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26. (Pubitemid 34429950)
6. Plessner HL, Lin PL, Kohno T, Louie JS, Kirschner D, Chan J, et al. Neutralization of tumor necrosis factor (TNF) by antibody but not TNF receptor fusion molecule exacerbates chronic murine tuberculosis. J Infect Dis 2007;195:1643-50. (Pubitemid 46799222)
7. Nesbitt A, Fossati G, Bergin M, Stephens P, Stephens S, Foulkes R, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis 2007;13:1323-32. (Pubitemid 350206841)
8. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104.
9. Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55:19-26. (Pubitemid 43235123)
10. Aguado JM, Herrero JA, Gavalda J, Torre-Cisneros J, Blanes M, Rufi G, et al. Clinical presentation and outcome of tuberculosis in kidney, liver, and heart transplant recipients in Spain. Spanish Transplantation Infection Study Group, GESITRA. Transplantation 1997;63:1278-86. (Pubitemid 27212823)
11. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tubercolosi e AIDS (GISTA). JAMA 1995;274:143-8.
12. Guelar A, Gatell JM, Verdejo J, Podzamczer D, Lozano L, Aznar E, et al. A prospective study of the risk of tuberculosis among HIV-infected patients. AIDS 1993;7:1345-9. (Pubitemid 23330305)
13. Meyers BR, Halpern M, Sheiner P, Mendelson MH, Neibart E, Miller C. Tuberculosis in liver transplant patients. Transplantation 1994;58:301-6. (Pubitemid 24252281)
14. Sakhuja V, Jha V, Varma PP, Joshi K, Chugh KS. The high incidence of tuberculosis among renal transplant recipients in India. Transplantation 1996;61:211-5. (Pubitemid 26044532)
15. Miller RA, Lanza LA, Kline JN, Geist LJ. Mycobacterium tuberculosis in lung transplant recipients. Am J Respir Crit Care Med 1995;152:374-6.
16. Sichletidis L, Settas L, Spyratos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10:1127-32. (Pubitemid 44519351)
17. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, Montero D, Pascual-Gomez E, Mola EM, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72. (Pubitemid 40852885)
18. Gomez-Reino JJ, Carmona L, Angel DM. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57:756-61. (Pubitemid 46932080)
19. Public Health Agency of Canada. Canadian tuberculosis standards. 6th ed. Ottawa: Public Health Agency of Canada; 2007. [Internet. Accessed February 15, 2011]. Available from: http://www.phac-aspc.gc.ca/tbpc-latb/pubs/pdf/tbstand07- e.pdf
20. American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;4 Part 2:S221-47.
21. The National Collaborating Centre for Chronic Conditions. Tuberculosis: clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London: Royal College of Physicians; 2006. [Internet. Accessed February 15, 2011]. Available from: http://www.nice.org.uk/nicemedia/ pdf/CG033FullGuideline.pdf
22. Canadian Tuberculosis Committee. Recommendations on interferon gamma release assays for the diagnosis of latent tuberculosis infection. An Advisory Committee Statement (ACS). Canada Communicable Disease Report (CCDR) V36(ACS-5). 2010. Ottawa: Public Health Agency of Canada; CCDR.
23. Mazurek GH, Jereb J, Vernon A, Lobue P, Goldberg S, Castro K. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection - United States. MMWR Morb Mortal Wkly Rep 2010;59:1-26.
24. British Thoracic Society Standards of Care Committee. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment. Thorax 2005;60:800-5.
25. Health Protection Agency Tuberculosis Programme Board. Health protection agency position statement on the use of interferon gamma release assay (IGRA) tests for tuberculosis (TB). London: Health Protection Agency. [Internet. Accessed February 15, 2011]. Available from: http://www.hpa.org.uk/web/ HPAwebFile/HPAweb-C/1204186168242
26. Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004;53:683-6.
27. Solovic I, Sester M, Gomez-Reino JJ, Rieder HL, Ehlers S, Milburn HJ, et al. The risk of tuberculosis related to TNF antagonist therapies: a TBNET consensus statement. Eur Respir J 2010;36:1185-206.
28. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis 2009;48:1429-32.
29. Vanhoof J, Landewe S, Van Wijngaerden E, Geusens P. High incidence of hepatotoxicity of isoniazid treatment for tuberculosis chemoprophylaxis in patients with rheumatoid arthritis treated with methotrexate or sulfasalazine and anti-tumour necrosis factor inhibitors. Ann Rheum Dis 2003;62:1241-2. (Pubitemid 37500639)
30. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008;35:1271-6. (Pubitemid 352000770)
31. Farhat M, Greenaway C, Pai M, Menzies D. False-positive tuberculin skin tests: what is the absolute effect of BCG and non-tuberculous mycobacteria? Int J Tuberc Lung Dis 2006;10:1192-204.
32. Centers for Disease Control and Prevention. Anergy skin testing and tuberculosis [corrected] preventive therapy for HIV-infected persons: revised recommendations. MMWR Recomm Rep 1997;46(RR-15):1-10.
33. American Thoracic Society. Diagnostic standards and classification of tuberculosis in adults and children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;4 Part 1:1376-95.
34. Sezer I, Kocabas H, Melikoglu MA, Arman M. Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy. Clin Rheumatol 2009;28:53-7.
35. Emery P, Panayi G, Symmons D, Brown G. Mechanisms of depressed delayed-type hypersensitivity in rheumatoid arthritis: the role of protein energy malnutrition. Ann Rheum Dis 1984;43:430-4. (Pubitemid 14117918)
36. Paimela L, Johansson-Stephansson EA, Koskimies S, Leirisalo-Repo M. Depressed cutaneous cell-mediated immunity in early rheumatoid arthritis. Clin Exp Rheumatol 1990;8:433-7. (Pubitemid 20362245)
37. Seitz M, Napierski I, Kirchner H. Depressed PPD and tetanus toxoid presentation by monocytes to T lymphocytes in patients with rheumatoid arthritis: restoration by interferon gamma. Rheumatol Int 1988;8:189-96. (Pubitemid 19003527)
38. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008;59:800-6.
39. Helliwell MG, Panayi GS, Unger A. Delayed cutaneous hypersensitivity in rheumatoid arthritis: the influence of nutrition and drug therapy. Clin Rheumatol 1984;3:39-45.
40. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, Cucho M, Alfaro J, Perich R, et al. Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 2005;64:1360-1. (Pubitemid 41206259)
41. Verwilghen J, Vertessen S, Stevens EA, Dequeker J, Ceuppens JL. Depressed T-cell reactivity to recall antigens in rheumatoid arthritis. J Clin Immunol 1990;10:90-8. (Pubitemid 20117243)
42. Tamborenea MN, Tate G, Mysler E, Debonis J, Schijedman A. Prevalence of positive ppd in a cohort of rheumatoid arthritis patients. Rheumatol Int 2010;30:613-6.
43. Schatz M, Patterson R, Kloner R, Falk J. The prevalence of tuberculosis and positive tuberculin skin tests in a steroid-treated asthmatic population. Ann Intern Med 1976;84:261-5.
44. Greenberg JD, Reddy SM, Schloss SG, Kurucz OS, Bartlett SJ, Abramson SB, et al. Comparison of an in vitro tuberculosis interferon-gamma assay with delayed-type hypersensitivity testing for detection of latent Mycobacterium tuberculosis: a pilot study in rheumatoid arthritis. J Rheumatol 2008;35:770-5. (Pubitemid 351747115)
45. Pope RM, Kniker WT, Talal N, Dauphinee M. Delayed type hypersensitivity in patients with rheumatoid arthritis. J Rheumatol 1993;20:17-20. (Pubitemid 23049176)
46. Graham NM, Nelson KE, Solomon L, Bonds M, Rizzo RT, Scavott J, et al. Prevalence of tuberculin positivity and skin test anergy in HIV-1-seropositive and -seronegative intravenous drug users. JAMA 1992;267:369-73.
47. Lee SS, Chou KJ, Su IJ, Chen YS, Fang HC, Huang TS, et al. High prevalence of latent tuberculosis infection in patients in end-stage renal disease on hemodialysis: Comparison of QuantiFERON-TB GOLD, ELISPOT, and tuberculin skin test. Infection 2009;37:96-102.
48. Pascual-Ramos V, Hernandez-Cruz B, Villalobos I, Sifuentes-Osornio J, Alcocer-Varela J. Purified protein derivative reaction in systemic lupus erythematosus patients. Indirect study of cellular immunity. Lupus 2002;11:25-30. (Pubitemid 34178116)
49. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008;149:177-84.
50. Bruzzese E, Bocchino M, Assante LR, Alessio M, Bellofiore B, Bruzzese D, et al. Gamma interferon release assays for diagnosis of tuberculosis infection in immune-compromised children in a country in which the prevalence of tuberculosis is low. J Clin Microbiol 2009;47:2355-7.
51. Mateo L, Mínguez S, Latorre I, Domínguez J, Moltó A, García E, et al. Usefulness of in vitro interferon-γ release assays (IGRAS) for diagnosis of latent tuberculosis infection in rheumatic patients scheduled for anti-TNF-α treatment [abstract]. Arthritis Rheum 2009;59 Suppl:996.
52. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, et al. QuantiFERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009;33:586-93.
53. Behar SM, Shin DS, Maier A, Coblyn J, Helfgott S, Weinblatt ME. Use of the T-SPOT.TB assay to detect latent tuberculosis infection among rheumatic disease patients on immunosuppressive therapy. J Rheumatol 2009;36:546-51.
54. Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008;27:907-13.
55. Inanc N, Aydin SZ, Karakurt S, Atagunduz P, Yavuz S, Direskeneli H. Agreement between quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2009;36:2675-81.
56. Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J, et al. Comparison of interferon-gamma release assays and conventional screening tests before tumour necrosis factor-alpha blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010;69:181-5.
57. Murakami S, Takeno M, Kirino Y, Kobayashi M, Watanabe R, Kudo M, et al. Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis. Tuberculosis (Edinb) 2009;89:136-41.
58. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008;35:776-81. (Pubitemid 351747116)
59. Sellam J, Hamdi H, Roy C, Baron G, Lemann M, Puechal X, et al. Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy. Ann Rheum Dis 2007;66:1610-5. (Pubitemid 350205449)
60. Marques CD, Duarte AL, de Lorena VM, Souza JR, Souza WV, de Miranda Gomes Y, et al. Evaluation of an interferon gamma assay in the diagnosis of latent tuberculosis infection in patients with rheumatoid arthritis. Rheumatol Int 2009 Apr 11. E-pub ahead of print.
61. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009;36:2158-63.
62. Laffitte E, Janssens JP, Roux-Lombard P, Thielen AM, Barde C, Marazza G, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009;161:797-800.
63. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, et al. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006;8:R114.
64. Giardina AR, Accardo-Palumbo A, Ciccia F, Ferrante A, Principato A, Impastato R, et al. Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vgamma9/Vdelta2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis? Reumatismo 2009;61:21-6.
65. Cobanoglu N, Ozcelik U, Kalyoncu U, Ozen S, Kiraz S, Gurcan N, et al. Interferon-gamma assays for the diagnosis of tuberculosis infection before using tumour necrosis factor-alpha blockers. Int J Tuberc Lung Dis 2007;11:1177-82. (Pubitemid 350146297)
66. Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008;67:84-90.
67. Kunimoto D, Der E, Beckon A, Thomas L, Egedahl M, Beatch A, et al. Use of the QuantiFERON-TB Gold test to confirm latent tuberculosis infection in a Canadian tuberculosis clinic. Int J Tuberc Lung Dis 2009;13:726-30.
68. ClinicalTrials.gov. Comparison of the tuberculin skin test (TST) and QuantiFERON®-TB gold test (QFT-G) in patients with rheumatoid arthritis being considered for anti-TNF-alpha therapy. ClinicalTrials.gov Identifier: NCT00925249. Bethesda: National Institutes of Health; 2009. [Internet. Accessed February 15, 2011] Available from: http://clinicaltrials.gov/ct2/show/ NCT00925249?term=NCT00925249&rank=1
69. Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. Arthritis Rheum 2009;61:300-4.
70. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. Arthritis Rheum 2002;46:2294-300.
71. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84. (Pubitemid 351847559)